Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AKNA domain containing 1 (AKNAD1) is a human protein encoded by the gene AKNAD1 (C1orf62, MGC26989), which contains a domain characteristic of AT-hook-containing transcription factors, although it is not itself a well-characterized transcription factor[1][3]. It is involved in several biological pathways, serving potential roles in endoplasmic reticulum-associated processes and cellular stress responses. AKNAD1 has shown disease relevance as a gene whose copy number variation is associated with type 2 diabetes and whose expression is implicated in both glioma prognosis and muscle differentiation under inflammatory conditions. It also features in multi-gene risk models for stratifying patient outcome in cancers, such as gliomas and HER2-positive breast cancer, thus suggesting use as a prognostic biomarker. There are no approved drugs known to directly interact with AKNAD1, and its precise functional mechanisms in health and disease remain incompletely understood[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AKNA domain containing 1 (AKNAD1).